Revenue Recognition from Collaboration and License Agreements - Additional Information (Details) - Collaboration and License Agreement - USD ($) $ in Millions	1 Months Ended			3 Months Ended		6 Months Ended
	Jun. 30, 2025	Mar. 31, 2024	May 31, 2020	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Feb. 29, 2024	Dec. 31, 2023
Bristol-Myers Squibb Company
Disaggregation of Revenue [Line Items]
Deferred revenue recognized				$ 0.3	$ 0.0	$ 0.3	$ 2.6
Collaboration term expiration date			Nov. 30, 2023
Bristol-Myers Squibb Company \| Undruggable targets
Disaggregation of Revenue [Line Items]
Deferred revenue recognized		$ 2.6
Option fee payment		0.1
Bristol-Myers Squibb Company \| Druggable targets
Disaggregation of Revenue [Line Items]
Deferred revenue recognized	$ 0.3
Bristol-Myers Squibb Company \| Maximum
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received			$ 301.0
Bristol-Myers Squibb Company \| Maximum \| Research, Development and Regulatory Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received			176.0
Bristol-Myers Squibb Company \| Maximum \| Commercial Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received			$ 125.0
Roche
Disaggregation of Revenue [Line Items]
Milestones payments received								$ 40.0
Deferred revenue recognized				$ 0.0	$ 1.1	$ 0.0	$ 50.9
Roche \| Third Additional Clinical Development Plan
Disaggregation of Revenue [Line Items]
Collaboration revenue received		$ 4.0
Collaboration revenue receivable earned									$ 2.1